These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8866937)

  • 1. Analgesic effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients with chronic pain.
    Takagi H; Harima A
    Eur Neuropsychopharmacol; 1996 Mar; 6(1):43-7. PubMed ID: 8866937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse.
    Kawabata A; Kasamatsu K; Umeda N; Takagi H
    Br J Pharmacol; 1994 Feb; 111(2):503-8. PubMed ID: 7911717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine.
    Iida N; Tsubakihara Y; Shirai D; Imada A; Suzuki M
    Nephrol Dial Transplant; 1994; 9(8):1130-5. PubMed ID: 7800213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M; Ogawa N; Ujike H
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N; Koshikawa S; Akizawa T; Tsubakihara Y; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M
    Am J Nephrol; 2002; 22(4):338-46. PubMed ID: 12169865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
    Yoshida M; Noguchi S; Kuramoto S
    Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.
    Suzuki T; Higa S; Sakoda S; Ueji M; Hayashi A; Takaba Y; Nakajima A
    Eur J Clin Pharmacol; 1982; 23(5):463-8. PubMed ID: 6818040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
    Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF
    J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
    Ujike H; Yamamoto M
    J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.
    Morimoto S; Matsumura Y; Ohyama T; Shinyama H; Ichihara T; Takahashi Y; Hisaki K
    Jpn J Pharmacol; 1990 Mar; 52(3):431-9. PubMed ID: 2110272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat renal tissues.
    Soares-da-Silva P
    Gen Pharmacol; 1993 Jan; 24(1):75-81. PubMed ID: 8482506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy.
    Ando Y; Gotoh T; Kawaguchi Y; Tanaka Y; Sakashita N; Ando M
    Pharmacotherapy; 1995; 15(3):345-9. PubMed ID: 7667168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
    Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
    J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.
    Araki H; Tanaka C; Fujiwara H; Nakamura M; Ohmura I
    J Pharm Pharmacol; 1981 Dec; 33(12):772-7. PubMed ID: 6121848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of harmaline induced tremor by L-threo-3, 4-dihydroxyphenylserine, an L-norepinephrine precursor].
    Yamazaki M; Ikeda Y; Ishikawa M; Inagaki C; Tanaka C
    Nihon Yakurigaku Zasshi; 1976 Apr; 72(3):363-9. PubMed ID: 986992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.